New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6531-6552

  La Regina, Giuseppe ^a   Bai, Ruoli ^b   Coluccia, Antonio ^a   Famiglini, Valeria ^a   Pelliccia, Sveva ^c   Passacantilli, Sara ^a   Mazzoccoli, Carmela ^d   Ruggieri, Vitalba ^d   Sisinni, Lorenza ^d   Bolognesi, Alessio ^e   Rensen, Whilelmina Maria ^e   Miele, Andrea ^e   Nalli, Marianna ^a   Alfonsi, Romina ^a   Di Marcotullio, Lucia ^a   Gulino, Alberto ^a   Brancale, Andrea ^f   Novellino, Ettore ^c   Dondio, Giulio ^g,j   Vultaggio, Stefania ^h   Varasi, Mario ^h   Mercurio, Ciro ⁱ   Hamel, Ernest ^b   Lavia, Patrizia ^e   Silvestri, Romano ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e Istituto Di Biologia E Patologia Molecolari Rome   (Italy)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g NiKem Research   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ Genextra Group   (Italy)

^j Aphad Srl   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(1 (3 AMINOPHENYL) 1H PYRROL 3 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; 1 (3 (3 (3,4,5 TRIMETHOXYBENZOYL) 1H PYRROL 1 YL)PHENYL)GUANIDINE HYDROCHLORIDE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; COLCHICINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN; PYRROLE DERIVATIVE; SONIC HEDGEHOG PROTEIN; TUBULIN; UNCLASSIFIED DRUG; (1-(3-AMINOPHENYL)-1H-PYRROL-3-YL)(3,4,5-TRIMETHOXYPHENYL)METHANONE; 1-(3-(3-(3,4,5-TRIMETHOXYBENZOYL)-1H-PYRROL-1-YL)PHENYL)GUANIDINE; ANILINE DERIVATIVE; GUANIDINE DERIVATIVE; PROTEIN BINDING; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; MEDULLOBLASTOMA CELL LINE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MOLECULAR MODEL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MOLECULAR DOCKING; NEOPLASMS; PATHOLOGY; POLYMERIZATION; SYNTHESIS; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; GUANIDINES; HEDGEHOG PROTEINS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MOLECULAR DOCKING SIMULATION; NEOPLASMS; POLYMERIZATION; PROTEIN BINDING; PYRROLES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 84906094556     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500561a     Document Type: Article

References (42)

1. Cancer; Fact Sheet No. 297; World Health Organization: Geneva, January 2013; http://www.who.int/mediacentre/factsheets/fs297/en/.
2. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Anti-mitotic acticity of colchicine and the structural basis for its interaction with tubulin Med. Res. Rev. 2008, 28, 155-183
3. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202
4. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding to colchicine to tubulin Biochemistry 1989, 28, 6984-6991
5. Nogales, E.; Whittaker, M.; Milligan, R. A.; Downing, K. H. High-resolution model of the microtubule Cell 1999, 96, 79-88
6. Nettles, J. H.; Li, H.; Cornett, B.; Krahn, J. M.; Snyder, J. P.; Downing, K. H. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography Science 2004, 305, 866-869
7. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; Lopez, J. A.; Andreu, J. M.; Hamel, E.; Diaz, J. F. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites Nature Chem. Biol. 2007, 3, 117-125
8. Beckers, T.; Mahboobi, S. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy Drugs Future 2003, 28, 767-785
9. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nature Rev. Cancer 2004, 4, 253-265
10. Teicher, B. A. Newer cytotoxic agents: attacking cancer broadly Clin. Cancer Res. 2008, 14, 1610-1617
11. Marzo, I.; Naval, J. Antimitotic drugs in cancer chemotherapy. Promises and pitfall Biochem. Pharmacol. 2013, 86, 703-710
12. Schmidt, M.; Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs Drug Resist. Update 2007, 10, 162-181
13. La Regina, G.; Sarkar, T.; Bai, R.; Edler, M. C.; Saletti, R.; Coluccia, A.; Piscitelli, F.; Minelli, L.; Gatti, V.; Mazzoccoli, C.; Palermo, V.; Mazzoni, C.; Falcone, C.; Scovassi, A. I.; Giansanti, V.; Campiglia, P.; Porta, A.; Maresca, B.; Hamel, E.; Brancale, A.; Novellino, E.; Silvestri, R. New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies J. Med. Chem. 2009, 52, 7512-7527
14. La Regina, G.; Bai, R.; Rensen, W. M.; Di Cesare, E.; Coluccia, A.; Piscitelli, F.; Famiglini, V.; Reggio, A.; Nalli, M.; Pelliccia, S.; Da Pozzo, E.; Costa, B.; Granata, I.; Porta, A.; Maresca, B.; Soriani, A.; Iannitto, M. L.; Santoni, A.; Li, J.; Miranda Cona, M.; Chen, F.; Ni, Y.; Brancale, A.; Dondio, G.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Martini, C.; Hamel, E.; Lavia, L.; Novellino, E.; Silvestri, R. Towards highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors J. Med. Chem. 2013, 56, 123-149
15. Morice, C.; Wermuth, C. G. Ring Transformations. In The Practice of Medicinal Chemistry, 3rd ed.; Elsevier Ltd: Burlington, VT, 2008; Chapter 16.
16. Chen, J.; Wang, Z.; Li, C.-M.; Lu, Y.; Vaddady, P. K.; Meibohm, B.; Dalton, J. T.; Miller, D. D.; Li, W. Discovery of novel 2-aryl-4-benzoyl- imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents J. Med. Chem. 2010, 53, 7414-7427
17. Dorleans, A.; Gigant, B.; Ravelli, R. B. G.; Mailliet, P.; Mikol, V.; Knossow, M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13775-13779
18. Barbier, P.; Dorleans, A.; Devred, F.; Sanz, L.; Allegro, D.; Alfonso, C.; Knossow, M.; Peyrot, V.; Andreu, J. M. Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers J. Biol. Chem. 2010, 285, 31672-31681
19. Clauson-Kaas, N.; Tyle, Z. Preparation of cis and trans 2,5-dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, cis and trans 2,5-dimethoxy-2-(acetamidomethyl)-tetrahydrofuran and 1-phenyl-2- (acetamidomethyl)-pyrrole Acta Chem. Scand. 1952, 6, 667-670
20. Massarotti, A.; Coluccia, A.; Silvestri, R.; Sorba, G.; Brancale, A. The tubulin colchicine domain: a molecular modeling perspective ChemMedChem 2012, 7, 33-42
21. Rensen, W. M.; Roscioli, E.; Tedeschi, A.; Mangiacasale, R.; Ciciarello, M.; Di Gioia, S. A.; Lavia, P. RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner Oncogene 2009, 28, 1748-1758
22. Yang, X. H.; Sladek, T. L.; Liu, X.; Butler, B. R.; Froelich, C. J.; Thor, A. D. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis Cancer Res. 2001, 61, 348-354
23. Peukert, S.; Miller-Moslin, K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics ChemMedChem 2010, 5, 500-512
24. Manetti, F.; Faure, H.; Roudaut, H.; Gorojankina, T.; Traiffort, E.; Schoenfelder, A.; Mann, A.; Solinas, A.; Taddei, M.; Ruat, M. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family as Smoothened antagonists Mol. Pharmacol. 2010, 78, 658-665
25. Solinas, A.; Faure, H.; Roudaut, H.; Traiffort, E.; Schoenfelder, A.; Mann, M.; Manetti, F.; Taddei, M.; Ruat, M. Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity J. Med. Chem. 2012, 55, 1559-1571
26. Massa, S.; Di Santo, R.; Artico, M.; Costi, R.; Apuzzo, G.; Simonetti, G.; Artico, M. Novel in vitro highly active antifungal agents with pyrrole and imidazole moieties Med. Chem. Res. 1992, 2, 148-153
27. Biswanath, D.; Digambar, B. S.; Boddu, S. K.; Jayprakash, N. K. Novel approach for the synthesis of N-substituted pyrroles starting directly from nitro compounds in water Synth. Commun. 2012, 42, 548-553
28. Chen, W.; Wang, J. Synthesis of pyrrole derivatives from diallylamines by one-pot tandem ring-closing metathesis and metal-catalyzed oxidative dehydrogenation Organometallics 2013, 32, 1958-1963
29. Prakash Reddy, V.; Vijay Kumar, A.; Rama Rao, K. New strategy for the synthesis of N-aryl pyrroles: Cu-catalyzed C-N cross-coupling reaction of trans-4-hydroxy-l-proline with aryl halides Tetrahedron Lett. 2011, 52, 777-780
30. Ramesh, K.; Murthy, S. N.; Nageswar, Y. V. D. Synthesis of N-substituted pyrroles under catalyst-and solvent-free conditions Synth. Commun. 2012, 42, 2471-2477
31. Pregel, M. J.; Hirth, B. H.; Kane, J. L.; Qiao, S.; Gregory, J.; Cuff, L. Preparation of tetrahydroisoquinoline derivatives for treating diseases mediated by protein trafficking or chloride channel activity. U.S. Patent US 20050176761 A1, 11 Aug, 2005.
32. Hermange, P.; Gogsig, T. M.; Lindhardt, A. T.; Taaning, R. H.; Skrydstrup, T. Carbonylative Heck reactions using CO generated ex situ in a two-chamber system Org. Lett. 2011, 9, 2444-2447
33. Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Fournier Dit Chabert, J.; McGown, A. T.; Lawrence, N. J. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity Bioorg. Med. Chem. 2009, 22, 7698-7710
34. Molecular Operating Environment (MOE 2010.10); Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2010; http://www.chemcomp.com.
35. Wang, C.; Wu, H.; Katritch, V.; Han, G. W.; Huang, X. P.; Liu, W.; Siu, F. Y.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human smoothened receptor bound to an antitumour agent Nature 2013, 497, 338-343
36. Glide, version 5.5; Schrödinger, LLC: New York, 2009.
37. Korb, O.; Stützle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with plants J. Chem. Inf. Model. 2009, 49, 84-96
38. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791
39. PyMol Molecular Graphics System; www.pymol.org.
40. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-21
41. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 35, 62-76
42. Ruan, S.; Okcu, M. F.; Pong, R. C.; Andreeff, M.; Levin, V.; Hsieh, J. T.; Zhang, W. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin Clin. Cancer Res. 1999, 5, 197-202